At Biocon, we are driven by our passion to develop research -
driven cutting edge therapies. Our tryst with innovation has
enabled us to address the relatively unmet needs of our patients
through differentiated products in challenging therapeutic spaces. We have earned the trust of patients and doctors through our products that are safe, efficacious and affordable. We are
constantly engaged in pursuit of excellence to find solutions that
heal the world.
Biocon is India's largest and fully-integrated, innovation-led biopharmaceutical company. We are committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer.
Through innovative products and research services we are constantly enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. We have successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'.
Some of our key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody.
We have a rich pipeline of biosimilars and novel biologics at various stages of development including a high potential Insulin Tregopil.
As the largest Indian Insulins Company, we believe we have made a huge difference to millions of diabetic patients in India. Over the years Biocon has also emerged as a leading Indian oncology company making cancer-care 'affordable' and 'accessible' to patients in India.